TargetBeta
IL33R
interleukin 33 receptor · also IL-33R, ST2, FIT-1, ST2L · I-set domain containing
2 programs in company-led studies act on IL33R, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| astegolimab | Hoffmann-La Roche | phase 3 | 91 running | – | a judged reading |
| TQC2938 | Sino Biopharmaceutical | phase 2 | 32 running | – | the company's pipeline |
Conditions their studies are in
- Asthma, 2 programs
- Pulmonary Disease, Chronic Obstructive, 2 programs
- COVID-19, 1 program
- Dermatitis, Atopic, 1 program
- Nasal Polyps, 1 program
- Rhinitis, Allergic, Seasonal, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 17, 2027TQC2938 · Sino Biopharmaceutical · phase 2 · NCT06789289
- Jun 30, 2027astegolimab · Hoffmann-La Roche · phase 3 · NCT05878769
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.